

Thia- and Seleno-Heterocycles Containing Cycloamidine Substructures: Ring Contraction Reactions of 1,3,4-Thia-/Selenadiazines

Jan Fleischhauer^a, Rainer Beckert^a, David Hornig^a, Wolfgang Günther^a, Helmar Görls^b, and Vera Klimesova^c

^a Institute of Organic and Macromolecular Chemistry, Friedrich Schiller University, Humboldtstraße 10, D-07743 Jena, Germany

^b Institute of Inorganic and Analytical Chemistry, Friedrich Schiller University, Lessingstraße 8, D-07743 Jena, Germany

^c Department of Inorganic and Organic Chemistry, Faculty of Pharmacy, Charles University, 500 05 Hradec Kralove, Czech Republic

Reprint requests to Prof. Dr. R. Beckert. E-mail: Rainer.Beckert@uni-jena.de

Z. Naturforsch. **2008**, *63b*, 415 – 424; received January 8, 2008

In memoriam to Ariane Beutler (1978 – 2007)

1,3,4-Thia/selena-diazines proved to be suitable starting materials for ring contraction reactions. Treatment with acetic acid/water mixtures leads to highly substituted 1,3,4-thia/selenadiazoles. In addition, the selenadiazoles formed undergo a fast Dimroth-rearrangement to finally yield derivatives of 1,2,4-triazole. The structures of all new derivatives were confirmed by NMR experiments, mass spectroscopy, elemental analysis and X-ray structural analysis.

Key words: Ring Contraction, Dimroth Rearrangement, Triazoles, Thiadiazoles, Selenadiazoles


Introduction

Δ^2 -1,2-diazetines of type **1** are easily accessible by cyclization reactions of monoalkyl-hydrazines with bis-imidoylchlorides of oxalic acid [1]. Such four-membered heterocycles, which contain two nitrogen atoms in the ring positions 1 and 2, are quite rare, and only a few examples were reported. Therefore their application in synthetic chemistry is rather limited [2].


Previously, we showed that due to their inherent ring strain and weak bonds, Δ^2 -1,2-diazetines **1** are quite useful in a number of versatile ring transformation reactions [3]. For example, compounds of type **1** react with isothiocyanates and isoselenocyanates in a ring enlargement reaction to yield 1,3,4-thiadiazines **2** and 1,3,4-selenadiazines **3**, respectively, with a wide variability of substitution patterns (Scheme 1) [4].

Being part of the heterocarbonyl systems in derivatives **2** and **3**, the imino substructures allow partial modifications of their backbones. Therefore one aim of our work was the formation of the corresponding oxo derivatives. Due to the different electronic and steric environments of the imino groups, several regioisomers **4**, **5** as well as the dioxo derivatives **6** could be expected [5]. In addition, these functionalities are often the subject of 1,3-acyl rearrangement reactions, finally resulting in derivatives of types **7** and **8**. During the course of our previous research, we have studied such Dimroth rearrangements on different five-membered heterocycles. As an important result we showed that they can be employed in the synthesis of new conjugated thioxo systems [6].

Furthermore, the ring contraction reactions of 1,3,4-thiadiazines **2** are well studied in the literature. The



Scheme 1. Ringtransformations of 1,2-diazetines **1** to yield 1,3,4-thia(selena)diazines **2**, **3**.




- 4 E = S/Se, Y = NAr, Z = O
 5 E = S/Se, Y = O, Z = NR
 6 E = S/Se, Y = O, Z = O
 7 E = NR, Y = NAr, Z = S/Sc
 8 E = NAr, Y = S/Sc, Z = NR

- 9 Y = NR, Z = N-NHMe
 10 Y = N-NHMe, Z = NR

11

Scheme 2. Possible products of hydrolysis and ring contraction reactions starting from **2** and **3**.



Scheme 3. Hydrolysis reaction of heterodiazines **2a–f/3a–c**.

products obtained show a remarkable dependence on the reaction conditions as well as on their substitution patterns [7]. For example, different 1,3-thiazoles were synthesized by the acid-catalyzed hydrolysis of **2** [8]. Similarly, 2-aminothiazoles **9** or thiazolyl-2-hydrazines **10** proved to be possible products in a ring contraction reaction. This useful method was recently employed by Pfeiffer *et al.* in order to make pyrazoles accessible which possess an unusual pattern of substituents [9]. In our case, this protocol should lead to pyrazoles of type **11** allowing further transformations which offer good requirements for the formation of metal chelate complexes (Scheme 2). These heterocycles should be of interest with respect to biological and pharmaceutical applications [10]. However, difficulties in the preparation of such compounds hamper their application.

Results and Discussion

Surprisingly, the hydrolysis reaction of **2** or **3** in acetic acid/water mixtures (10:1) did not result in




Fig. 1. Molecular structure of derivative **12b** in the solid state as determined by X-ray analysis.

any of the expected products listed in Scheme 2. In a complex reaction, not only the 1,3,4-thia-/selenadiazoles **12/13** were isolated as main products but also the 1,3,4-triazoles **15/16** were formed. Nearly the same product distribution was observed upon treatment of the starting materials **2/3** in glacial acetic acid. The acetylated arylamines **14** were formed as byproducts in equimolar amounts (Scheme 3). The structural assignment shown in Scheme 3 was confirmed by NMR and MS data, elemental analysis and single crystal X-ray structural analysis for the compounds **12b**, **12e**, **13a** and **15a** (Figs. 1–3).




Fig. 2. Molecular structure of derivative **13a** in the solid state as determined by X-ray analysis.

Common synthetic methods to obtain 2-imino-substituted 1,3,4-thia-/selenadiazoles often apply the [2+3]-cycloaddition reaction between hydrazonoyl halides and thio-/selenocarbonyl derivatives [11]. Recently, Firsova *et al.* reported a 2-thioxo-1,3-thiazole as dipolarophile, which strongly limited the variability of substituents at the imino group [11f]. Other authors used carbodithioates and thiocarbamates, respectively, as thioxo components in order to prepare 2-imino-substituted 1,3,4-thiadiazoles [11a–e]. To the best of our knowledge, only one example exists in the literature: the ring contraction reaction of 6-hydroxyimino-tetrahydro-1,3,4-thiadiazine-2-thiones to 3-methyl-5-phenyl-1,3,4-thiadiazole-2(3*H*)-thiones [12]. Analogous ring transformation reactions finally leading to highly substituted 1,3,4-thiadiazoles **12** and 1,3,4-selenadiazoles **13** are unknown.

In order to test the scope and limitations of this mild ring contraction reaction, a variety of aliphatic as well as aromatic substituted thia/selenadiazines was employed. As demonstrated in Scheme 3, this method can be applied to a wide range of substituents at the educts. Due to different electronic and steric effects, the achieved yields and the reaction times differ. In the case of 1,3,4-selenadiazines **3**, a second side reaction was observed. Under the conditions applied for hydrolysis of derivatives **3**, a further product was isolated in a yield of approximately 20 %. The X-ray crystal structural analysis revealed that an additional Dimroth rearrangement leading to 4-aryl-1-methyl-5-selenoxo-1,2,4-triazole-3-carboxamide **15** took place (Scheme 3, Fig. 3). The easy cleavage of the C(2)–Se bond, which is considerably elongated compared to the C(2)–S bond, might be the explanation for this final rearrangement. Similarly, 3-selenoxo-1,2,4-triazoles were obtained by reactions of isoselenocyanates with phenylhydrazines or *S*-methyl-isothiosemicarbazides [13].

Compounds **12/13** are colorless (R = aliphatic) or pale yellow (R = aromatic) crystalline solids that are





Fig. 3. Molecular structure of derivative **15a** in the solid state as determined by X-ray analysis.

remarkably stable in solution. Even after standing in CDCl₃ for a prolonged period, no decomposition of the selenacycles **13** was detected by NMR spectroscopy. In contrast, the selenones **15** decompose by irradiation with UV light under the loss of selenium.


In both **12b** and **13a**, the proton is located at the exocyclic atom N(3) and forms a very weak intramolecular hydrogen bond to N(2) [N(2)–H = 2.42 Å (**12b**); 2.39 Å (**13b**)]. The ring bonding angles are significantly influenced by the chalcogen atom. A relatively small C1–E–C2 angle (**12b** = 88.29°; **13b** = 83.83°) is compensated by a widening of the C1–N1–N2 and N2–C2–E angles. The arylamide moiety as well as the imine substituent at N4 show a *cis*-arrangement with respect to the chalcogen atom. The arylamide moiety is slightly twisted out of plane of the heterodiazole substructure. In the ¹³C NMR spectra, the carbon of the N–C=Se group in **15** resonates at a significantly lower field than the one of the Se–C=N in **13** (δ ≈ 140 ppm [**13**], 170 ppm [**15**]). In their ⁷⁷Se NMR spectra the signals for the selenium nucleus appear at about 500 ppm for **13** and 100 ppm for **15**.



Scheme 4. Regioselective ring transformation reactions of **1a** and **2f**.

In view of mechanistic investigations for these ring contraction reactions, unsymmetrically substituted Δ^2 -1,2-diazetines **1a** with respect to their aromatic substituents ($\text{Ar} \neq \text{Ar}'$) were used. These derivatives could be obtained by a four-step protocol starting from ethyl (chlorocarbonyl) formate and 2,4,6-trimethylbenzenamine. The four-membered ring system of **1a** proved to be unstable and was thus applied directly in the ring transformation reaction with 4-*tert*-butylphenyl isothiocyanate without further purification. The structure of product **2f** was confirmed by NMR and mass spectroscopy, elemental analysis and X-ray structural analysis. The arrangement of substituents in **2f** clearly underlines the regioselectivity of this cycloacylation reaction (Scheme 4).

The hydrolysis reaction of **2f** ($\text{Ar} \neq \text{Ar}'$) resulted in only one product with the 4-bromophenyl substituent ($\text{Ar} = 4\text{-BrC}_6\text{H}_4$) at the position of the aromatic amide. Consequently, in the course of the hydrolysis, the mesidine moiety is liberated ($\text{Ar} = 2,4,6\text{-(CH}_3)_3\text{C}_6\text{H}_2$). This important experimental finding suggests the following mechanism (Scheme 5): First, a protonation reaction under formation of the iminium salt **A** takes place. Due to the existence of amino/imino as well as amidine substructures in the molecules of **2/3**, dynamic protonation and deprotonation equilibria in acidic media exist. The iminium salt **A** can be regarded as a key intermediate in which the chalcogen atom attacks the activated C(5)-





Scheme 5. Postulated mechanism of the hydrolysis reaction of heterocycles **2/3**.

position. Then the attack of water at C(6) causes a bond cleavage between C(6) and the chalcogen atom E. The resulting semicyclic aminal **B** is not stable under these conditions and quickly decomposes under acid catalysis into H⁺/Ar'-NH₂ and **12** or **13**. The transformation of **13** into **15** can easily be explained by a Dimroth rearrangement reaction which often takes place under acidic catalysis or at higher temperatures. Finally, the eliminated arylamine (Ar'-NH₂) is acetylated to yield derivative **14**.

Generally, the hydrolysis reaction could be applied to acyl-substituted derivatives as shown in example **2e**. However, influenced by the higher electrophilicity of the ring carbon atoms, an increasing number of side reactions was observed. The products and mechanisms of their formation have not yet been fully investigated. For example, no thiadiazole derivatives could be isolated upon hydrolysis of the acetyl derivative **2g** (Scheme 6).

We assume that in this case a desacetylation reaction is the first step which generates the free NH group (**C**) followed by the nucleophilic attack of water and a ring-opening/ring-closure sequence (**D**). The final cyclization product **16**, a derivative of 1,2,4-triazole with an exocyclic thiocarboxamide substructure (Scheme 6), was isolated in about 40% yield. The result of a single crystal X-ray analysis clearly demonstrated that the NH nitrogen was integrated into the five-membered ring (Fig. 4).

Biological tests of similar compounds such as 3-phenyl-2-*N*-arylimino-2,3-dihydro-1,3,4-thiadiazoles

Scheme 6. Acidic hydrolysis of thiadiazine **2g**.Fig. 4. Molecular structure of derivative **16** in the solid state as determined by X-ray analysis.

[10c] have shown that they exhibit antibacterial and fungicide activity. First biological tests of our compounds showed activity against *M. tuberculosis*, *M. avium* und *M. kansasii* which is similar to that of the reference standard (INH). The modification of these derivatives with respect to new leading structures, especially against resistant bacterial and fungicide strains, will be the subject of further studies.

Conclusions

A new and useful method for the synthesis of 1,3,4-thia-/selenadiazoles **12/13** was presented employing easily accessible heterodiazines **2, 3** (E = S, Se). In the series of selenacycles, 1,3,4-triazoles of type **15**

were isolated as additional products. This new ring contraction method is applicable to a wide range of substituents R as well as Ar in the starting materials. We are currently investigating further ring transformation reactions, especially those of corresponding acyl derivatives. The results will be reported in a forthcoming article.

Experimental Section

All solvents were dried and purified by standard techniques. The reagents employed were of commercial quality (Aldrich, Lancaster, Fluka, Merck). Reactions were monitored by TLC using aluminum plates coated with Al₂O₃ or SiO₂ from Fluka. Melting points were measured with a digital detector system KSPS 1000 from Krüss and with a B-545 (Boetius system) from Büchi and are uncorrected. The ¹H and ¹³C NMR spectra were obtained on a Bruker AC 250 (250 MHz) or Bruker DRC-400 (400 MHz) spectrometer. ⁷⁷Se NMR spectra (76 MHz) were obtained on a Bruker DRC-400 spectrometer using Me₂Se as external (⁷⁷Se) standard. Mass spectra were measured on a spectrometer Trio 2000 from Fisons. Elemental analyses were carried out with an automatic analyzer Varion EL III from Elementar Analysensysteme GmbH.

Crystal structure determinations

Intensity data for the compounds were collected on a Nonius KappaCCD diffractometer using graphite-monochromatized MoK_α radiation. The data were corrected for Lorentz and polarization effects but not for absorption [14, 15]. The structures were solved by Direct Methods (SHELXS-97) and refined by full-matrix least-squares methods on F_o² (SHELXL-97) [16, 17]. In all cases the hydrogen atom of the amino group N(3) was located in a difference Fourier synthesis and refined isotropically. The other hydrogen atoms were included at calculated positions with fixed thermal parameters. All non-hydrogen atoms were refined anisotropically. The program XP was used for structure representations [18]. Crystal data and refinement details are summarized in Table 1, selected bond lengths and angles in Table 2.

*N*¹-(4-Bromo-phenyl)-*N*²-mesityl-oxalodiimidoyl dichloride was prepared starting from ethyl (mesitylamino)oxoacetate [19a] which was heated under reflux with 4-bromoaniline in xylene for several days to give the *N*¹-(4-bromophenyl)-*N*²-mesityloxalamide [19b]. The latter was chlorinated following the general protocol [19c] for *bis*-imidoylchlorides (in toluene with phosphorus pentachloride) to give the *N*¹-(4-bromo-phenyl)-*N*²-4-mesityl-oxalodiimidoyl dichloride [19d].

Table 1. Crystal data and refinement details for the X-ray structure determinations.

Compound	2f	12b	12e	13a	15a	16
Formula	C ₂₉ H ₃₂ BrN ₅ S	C ₁₃ H ₁₆ N ₄ OS	C ₁₈ H ₁₆ N ₄ O ₂ S	C ₁₈ H ₁₈ N ₄ O ₂ Se	C ₁₈ H ₁₈ N ₄ O ₂ Se	C ₁₁ H ₁₂ N ₄ OS
<i>M</i> _w , g · mol ^{−1}	562.57	276.36	352.41	401.32	401.32	248.31
<i>T</i> , °C	−90(2)	−90(2)	−90(2)	−90(2)	−90(2)	−90(2)
Crystal system	triclinic	triclinic	monoclinic	monoclinic	monoclinic	orthorhombic
Space group	<i>P</i> $\bar{1}$	<i>P</i> 2 ₁ / <i>n</i>	<i>P</i> 2 ₁ / <i>c</i>	<i>P</i> 2 ₁ / <i>n</i>	<i>P</i> 2 ₁ / <i>c</i>	<i>Pbca</i>
<i>a</i> , Å	9.3843(4)	9.7860(4)	7.9533(3)	8.4055(3)	5.6757(5)	8.8695(3)
<i>b</i> , Å	11.5017(7)	11.7752(4)	20.0780(6)	19.0862(4)	28.302(3)	9.1237(2)
<i>c</i> , Å	13.9601(7)	12.2790(5)	10.5065(4)	10.9646(4)	11.5359(9)	30.2125(8)
α , deg	104.602(2)	90.00	90.00	90.00	90.00	90.00
β , deg	98.079(3)	100.585(2)	94.331(2)	96.430(2)	104.148(5)	90.00
γ , deg	101.403(3)	90.00	90.00	90.00	90.00	90.00
<i>V</i> , Å ³	1400.26(13)	1390.86(9)	1672.95(10)	1747.97(10)	1796.8(3)	2444.88(12)
<i>Z</i>	2	4	4	4	4	8
ρ , g · cm ^{−3}	1.334	1.320	1.399	1.525	1.484	1.349
μ , cm ^{−1}	15.69	2.31	2.13	21.67	21.09	2.54
Measured data	9917	9182	11808	12217	6761	14828
Data with <i>I</i> ≥ 2σ(<i>I</i>)	4524	2316	2778	3097	2093	1962
Unique data / <i>R</i> _{int}	6347/0.0324	3149/0.0408	3836/0.0427	3986/0.0483	3565/0.0715	2797/0.0620
<i>R</i> ₁ [<i>I</i> ≥ 2σ(<i>I</i>)] ^a	0.045	0.040	0.047	0.034	0.061	0.045
<i>wR</i> ₂ (all data, on <i>F</i> ²) ^a	0.096	0.109	0.127	0.078	0.132	0.123
<i>S</i> ^b	1.008	1.008	1.007	1.005	1.015	1.033
Δρ _{fin} (max/min), e Å ^{−3}	0.33/−0.50	0.21/−0.22	0.58/−0.22	0.38/−0.45	0.50/−0.54	0.32/−0.34
CCDC No. ^c	671007	671008	671009	671010	671011	671012

^a Definition of the *R* indices: $R_1 = (\sum ||F_o| - |F_c||) / \sum |F_o|$; $wR_2 = \{\sum [w(F_o^2 - F_c^2)^2] / \sum [w(F_o^2)^2]\}^{1/2}$ with $w^{-1} = \sigma^2(F_o^2) + (aP)^2$; ^b *S* = $\{\sum [w(F_o^2 - F_c^2)^2] / (N_o - N_p)\}^{1/2}$; ^c CCDC 671007–671012 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Compound	2f	12b	12e	13a	15a	16
	E = S1	E = S	E = S1	E = Se1	E = N4	E = N3
(C1)–(E)	1.780(2)	1.7773(16)	1.7488(19)	1.932(2)	1.374(6)	1.365(2)
(C2)–(E)	1.766(2)	1.7401(17)	1.735(2)	1.879(2)	1.378(6)	1.367(3)
(C2)–(N2)		1.283(2)	1.290(3)	1.281(3)	1.298(6)	1.305(3)
(C1)–(N1)	1.365(3)	1.383(2)	1.355(2)	1.386(3)	1.336(6)	1.359(3)
(C1)–(N4)		1.271(2)	1.308(2)	1.272(3)		
(N1)–(N2)	1.387(3)	1.3573(18)	1.364(2)	1.357(2)	1.375(5)	1.381(2)
(C1)–(Se1)				1.844(5)		
(C1)–(O1)						1.241(2)
(C3)–(S1)						1.650(2)
(C3)–(N2)	1.289(3)					
(C3)–(C2)	1.473(3)					
(C1)–(E)–(C2)	103.17(11)	88.29(8)	87.67(9)	83.83(9)	107.1(4)	107.82(18)
(C1)–(N1)–(N2)	126.93(19)	117.30(13)	117.35(16)	119.64(18)	112.6(4)	112.34(16)
(N2)–(C2)–(Y)		116.28(12)	116.76(14)	116.43(16)	111.3(4)	112.04(17)
(N2)–(C3)–(C2)	126.5(2)					

Table 2. Selected bond lengths (Å) and angles (deg) for **2**, **12**, **13**, **15** and **16** with estimated standard deviations in parentheses.

1-Methyl-3-(mesitylamino)-4-(4-bromophenylimino)-Δ²-1,2-diazetine (1a)

A THF solution (30 mL) of the *bis*-imidoyl chloride described above (0.8 g, 2 mmol) and TEA (1.5 mL, 10 mmol) was cooled to 0 °C, and a solution of methylhydrazine (0.11 mL, 2 mmol) in 10 mL of THF was added dropwise. After complete conversion (as monitored by TLC), the reaction mixture was filtered to remove the TEA · HCl and was used without further purification for the following reaction.

Ring transformation reaction of 1a with 4-tert-butylphenyl-isothiocyanate to yield 2-(4-tert-butylphenylimino)-6-(4-bromophenylimino)-3,6-dihydro-N-mesityl-3-methyl-2H-1,3,4-thiadiazin-5-amine (2f)

To the cooled THF solution (30 mL) of **1a** (0.74 g, 2 mmol) was added dropwise a solution of 4-*tert*-butylphenyl-isothiocyanate (0.39 g, 2 mmol) in 5 mL of THF. The reaction mixture was warmed up to r. t. and stirred for 6 h. The solvent was removed *in vacuo*, and the residue was purified by column chromatography (Al₂O₃, chloroform/heptane

2:1). Recrystallization from chloroform/heptane gives the heterodiazine **2f** as yellow needles (0.87 g, 77 % yield), m. p. 186.8–187.1 °C. – ¹H NMR (250 MHz, CDCl₃): δ = 7.47 (d, *J* = 8.8 Hz, 2H, CH), 7.29 (d, *J* = 8.8 Hz, 2H, CH), 6.95 (s, 2H, CH), 6.90–6.71 (m, 5H, NH, CH), 3.78 (s, 3H, CH₃N), 2.33, 2.31 (2s, 9H, CH₃), 1.31 (s, 9H, C(CH₃)₃). – ¹³C NMR (63 MHz, CDCl₃): δ = 146.5, 146.0, 145.4, 144.2, 140.9, 135.8, 135.5, 135.0, 133.6, 132.5, 128.8, 126.2, 121.8, 121.2, 118.9 (C_{aryl}, C_{imin}), 43.5 (CH₃N), 34.3 (C(CH₃)₃), 31.4 (C(CH₃)₃), 21.0, 18.7 (CH₃). – MS (DEI): *m/z* = 563 [M, ⁸¹Br]⁺, 546, 380, 365, 247, 189, 176, 146, 131, 117, 91, 77, 41. – C₂₉H₃₂BrN₅S (562.6): calcd. C 61.91, H 5.73, N 12.45, S 5.70; found C 61.85, H 5.68, N 12.46, S 5.80.

Hydrolysis reaction of heterodiazines 2a–g and 3a–c to yield the heterodiazoles 12a–f/13a–c and heterotriazoles 15a–c/16

General procedure

A solution of 1 mmol of the corresponding heterodiazine, 10 mL of glacial acetic acid and 1 mL of water was stirred for approx. 2 h at 100–110 °C. After complete conversion (monitored by TLC; Al₂O₃; toluene/acetone 20:1), the solvent was removed *in vacuo*, and the residue was purified by column chromatography (Al₂O₃, toluene/acetone 50:1). Recrystallization from chloroform/heptane gives heterodiazoles **12/13** and triazoles **15/16**.

4,5-Dihydro-4-methyl-5-(methylimino)-*N*-*p*-tolyl-1,3,4-thiadiazole-2-carboxamide (**12a**)

This compound was obtained as colorless prisms (150 mg, 57 % yield), m. p. 143 °C. – ¹H NMR (250 MHz, CDCl₃): δ = 8.28 (s, 1 H, NH), 7.50 (d, *J* = 8.4 Hz, 2 H, CH), 7.17 (d, *J* = 8.0 Hz, 2 H, CH), 3.66, 3.09 (2 s, 6 H, CH₃N), 2.34 (s, 3 H, CH₃). – ¹³C NMR (63 MHz, CDCl₃): δ = 159.1, 155.5, 141.9, 134.6, 134.2, 129.7, 119.7 (C_{aryl}, C_{imin}), 43.1, 36.0 (CH₃N), 20.9 (CH₃). – MS (DEI): *m/z* = 262 [M]⁺, 174, 146, 133, 106, 102. – C₁₂H₁₄N₄OS (262.3): calcd. C 54.94, H 5.38, N 21.36, S 12.22; found C 54.98, H 5.36, N 21.33, S 12.09.

5-Ethylimino-4,5-dihydro-4-methyl-*N*-*p*-tolyl-1,3,4-thiadiazole-2-carboxamide (**12b**)

This compound was obtained as colorless prisms (259 mg, 97 % yield), m. p. 129 °C. – ¹H NMR (400 MHz, CDCl₃): δ = 8.29 (s, 1 H, NH), 7.51 (d, *J* = 8.6 Hz, 2 H, CH), 7.17 (d, *J* = 8.3 Hz, 2 H, CH), 3.65 (s, 3 H, CH₃N), 3.18 (q, *J* = 7.3 Hz, 2 H, CH₂), 2.35 (s, 3 H, CH₃), 1.31 (t, *J* = 7.3 Hz, 3 H, CH₃). – ¹³C NMR (100 MHz, CDCl₃): δ = 156.7, 155.7, 141.5, 134.5, 134.4, 129.7, 119.7 (C_{aryl}, C_{imin}), 52.2 (CH₂), 35.9 (CH₃N), 20.9, 15.4 (CH₃). – MS (DEI): *m/z* = 276 [M]⁺, 261, 174, 160, 146, 133, 106, 91, 69,

56. – C₁₃H₁₆N₄OS (276.4): calcd. C 56.50, H 5.84, N 20.27, S 11.60; found C 56.52, H 5.95, N 20.22, S 11.46.

5-Benzylimino-4,5-dihydro-4-methyl-*N*-*p*-tolyl-1,3,4-thiadiazole-2-carboxamide (**12c**)

This compound was obtained as colorless prisms (192 mg, 57 % yield), m. p. 140 °C. – ¹H NMR (250 MHz, CDCl₃): δ = 8.29 (s, 1 H, NH), 7.50 (d, *J* = 8.4 Hz, 2 H, CH), 7.33 (m, 5 H, CH), 7.18 (d, *J* = 8.2 Hz, 2 H, CH), 4.37 (s, 2 H, CH₂), 3.73 (s, 3 H, CH₃N), 2.34 (s, 3 H, CH₃). – ¹³C NMR (63 MHz, CDCl₃): δ = 158.0, 155.6, 141.6, 139.1, 134.6, 134.3, 129.7, 128.4, 127.6, 127.0, 119.7 (C_{aryl}, C_{imin}), 60.6 (CH₂), 36.0 (CH₃N), 20.9 (CH₃). – MS (DEI): *m/z* = 338 [M]⁺, 261, 204, 160, 133, 106, 91, 65, 56. – C₁₈H₁₈N₄OS (338.4): calcd. C 63.88, H 5.36, N 16.56, S 9.47; found C 63.70, H 5.39, N 16.54, S 9.43.

4,5-Dihydro-4-methyl-5-(4-methoxyphenylimino)-*N*-*p*-tolyl-1,3,4-thiadiazole-2-carboxamide (**12d**)

This compound was obtained as pale yellow prisms (227 mg, 64 % yield), m. p. 109 °C. – ¹H NMR (250 MHz, CDCl₃): δ = 8.32 (s, 1 H, NH), 7.50 (d, *J* = 8.4 Hz, 2 H, CH), 7.16 (d, *J* = 8.2 Hz, 2 H, CH), 7.02 (d, *J* = 9.2 Hz, 2 H, CH), 6.91 (d, *J* = 9.2, 2 H, CH), 3.81 (s, 3 H, CH₃O), 3.75 (s, 3 H, CH₃N), 2.33 (s, 3 H, CH₃). – ¹³C NMR (63 MHz, CDCl₃): δ = 156.7, 156.3, 155.5, 144.1, 141.5, 134.6, 134.3, 129.7, 121.6, 119.7, 114.9 (C_{aryl}, C_{imin}), 55.5 (CH₃O), 36.2 (CH₃N), 20.9 (CH₃). – MS (DEI): *m/z* = 354 [M]⁺, 338, 206, 165, 147, 106, 91, 78, 65. – C₁₈H₁₈N₄O₂S (354.4): calcd. C 61.00, H 5.12, N 15.81, S 9.05; found C 60.95, H 5.06, N 15.69, S 8.75.

5-Benzoylimino-4,5-dihydro-4-methyl-*N*-*p*-tolyl-1,3,4-thiadiazole-2-carboxamide (**12e**)

This compound was obtained as pale yellow prisms (140 mg, 40 % yield), m. p. 200 °C (dec.). – ¹H NMR (250 MHz, CDCl₃): δ = 8.41 (s, 1 H, NH), 8.32 (m, 2 H, CH), 7.48 (m, 5 H, CH), 7.16 (d, *J* = 8.2 Hz, 2 H, CH), 4.09 (s, 3 H, CH₃N), 2.32 (s, 3 H, CH₃). – ¹³C NMR (63 MHz, CDCl₃): δ = 174.4, 167.1 (C=O), 155.3, 151.9, 135.5, 135.0, 134.0, 132.4, 129.7, 129.6, 128.2, 119.8 (C_{aryl}, C_{imin}), 38.1 (CH₃N), 20.9 (CH₃). – MS (DEI): *m/z* = 352 [M]⁺, 275, 218, 164, 142, 105, 77, 51. – C₁₈H₁₆N₄O₂S (352.4): calcd. C 61.35, H 4.58, N 15.90, S 9.10; found C 61.11, H 4.60, N 15.84, S 9.32.

5-(4-*tert*-Butylphenylimino)-4,5-dihydro-4-methyl-*N*-(4-bromophenyl)-1,3,4-thiadiazole-2-carboxamide (**12f**)

This compound was obtained as pale yellow needles (285 mg, 64 % yield), m. p. 182.5–182.9 °C (dec.). – ¹H NMR (250 MHz, CDCl₃): δ = 8.37 (s, 1H, NH),

7.60–7.30 (m, 6H, CH), 7.02 (d, $J = 8.8$ Hz, 2H, CH), 3.77 (s, 3H, CH₃N), 1.34 (s, 9H, C(CH₃)₃). – ¹³C NMR (63 MHz, CDCl₃): $\delta = 156.3, 155.6, 147.7, 147.2, 141.3, 135.9, 132.2, 126.5, 121.3, 120.0, 117.5$ (C_{aryl}, C_{imin}), 36.4 (CH₃N), 34.4 (C(CH₃)₃), 31.4 (C(CH₃)₃). – MS (DEI): $m/z = 446$ [M, ⁸¹Br]⁺, 431, 232, 215, 173, 145, 91, 44, 28. – C₂₀H₂₁BrN₄OS (445.4): calcd. C 53.94, H 4.75, Br 17.94, N 12.58, S 7.20; found C 53.91, H 4.72, Br 18.40, N 12.61, S 7.31.

4,5-Dihydro-4-methyl-5-(4-methoxyphenylimino)-N-p-tolyl-1,3,4-selenadiazole-2-carboxamide (13a)

This compound was obtained as pale yellow prisms (221 mg, 55 % yield), m.p. 101.6–102.8 °C. – ¹H NMR (250 MHz, CDCl₃): $\delta = 8.32$ (s, 1H, NH), 7.51 (d, $J = 8.4$ Hz, 2H, CH), 7.16 (d, $J = 8.4$ Hz, 2H, CH), 7.06–6.88 (m, 4H, CH), 3.81, 3.79 (2s, 6H, CH₃O, CH₃N), 2.33 (s, 3H, CH₃). – ¹³C NMR (63 MHz, CDCl₃): $\delta = 158.8, 157.0, 156.6, 146.0, 143.0, 142.1, 134.5, 134.4, 129.7, 120.9, 119.7, 115.1$ (C_{aryl}, C_{imin}), 55.5 (CH₃O), 37.0 (CH₃N), 20.9 (CH₃). – ⁷⁷Se NMR (76 MHz, CDCl₃): $\delta = 520.4$ (s). – MS (DEI): $m/z = 402$ [M, ⁸⁰Se]⁺, 385, 254, 213, 162, 147, 133, 121, 106, 91, 77, 28. – C₁₈H₁₈N₄O₂Se (401.3): calcd. C 53.87, H 4.52, N 13.96; found C 53.87, H 4.51, N 13.88.

5-(4-Bromophenylimino)-4,5-dihydro-4-methyl-N-p-tolyl-1,3,4-selenadiazole-2-carboxamide (13b)

This compound was obtained as pale yellow prisms (194 mg, 43 % yield), m.p. 181.5–182.3 °C. – ¹H NMR (250 MHz, CDCl₃): $\delta = 8.31$ (s, 1H, NH), 7.60–7.42 (m, 4H, CH), 7.17 (d, $J = 8.2$ Hz, 2H, CH), 6.94 (d, $J = 8.8$ Hz, 2H, CH), 3.81 (s, 3H, CH₃N), 2.34 (s, 3H, CH₃). – ¹³C NMR (63 MHz, CDCl₃): $\delta = 159.8, 156.7, 151.5, 143.8, 134.6, 134.3, 132.9, 129.7, 121.8, 119.7, 117.3$ (C_{aryl}, C_{imin}), 37.1 (CH₃N), 20.9 (CH₃). – ⁷⁷Se NMR (76 MHz, CDCl₃): $\delta = 526.8$ (s). – MS (DEI): $m/z = 450$ [M, ⁸⁰Se⁷⁹Br]⁺, 402, 344, 290, 261, 210, 196, 174, 161, 146, 133, 118, 106, 91, 83, 77, 56, 28. – C₁₇H₁₅BrN₄OSe (450.2): calcd. C 45.35, H 3.36, Br 17.75, N 12.45; found C 45.37, H 3.35, Br 18.40, N 12.59.

5-(4-tert-Butylphenylimino)-4,5-dihydro-4-methyl-N-p-tolyl-1,3,4-selenadiazole-2-carboxamide (13c)

This compound was obtained as pale yellow prisms (286 mg, 67 % yield), m.p. 117.9–118.8 °C. – ¹H NMR (250 MHz, CDCl₃): $\delta = 8.34$ (s, 1H, NH), 7.52 (d, $J = 8.4$ Hz, 2H, CH), 7.41 (d, $J = 8.6$ Hz, 2H, CH), 7.17 (d, $J = 8.2$ Hz, 2H, CH), 7.01 (d, $J = 8.6$ Hz, 2H, CH), 3.81 (s, 3H, CH₃N), 2.34 (s, 3H, CH₃), 1.35 (s, 9H, C(CH₃)₃). – ¹³C NMR (63 MHz, CDCl₃): $\delta = 158.4, 157.0, 149.7, 147.4, 143.2, 134.5, 134.4, 129.7, 126.7, 119.7, 119.3$ (C_{aryl}, C_{imin}), 37.0 (CH₃N), 34.4 (C(CH₃)₃), 31.4 (C(CH₃)₃), 20.9 (CH₃). –

⁷⁷Se NMR (76 MHz, CDCl₃): $\delta = 521.2$ (s). – MS (DEI): $m/z = 428$ [M, ⁸⁰Se]⁺, 413, 224, 206, 173, 158, 145, 133, 117, 106, 91, 77, 65, 28. – C₂₁H₂₄N₄OSe (427.4): calcd. C 59.01, H 5.66, N 13.11; found C 59.09, H 5.73, N 13.19.

4,5-Dihydro-4-(4-methoxyphenyl)-1-methyl-5-selenoxo-N-p-tolyl-1H-1,2,4-triazole-3-carboxamide (15a)

This compound was obtained as colorless needles (64 mg, 16 % yield), m.p. 233.4–234.6 °C (dec.). – ¹H NMR (250 MHz, CDCl₃): $\delta = 8.48$ (s, 1H, NH), 7.42 (d, $J = 8.6$ Hz, 2H, CH), 7.27 (d, $J = 8.8$ Hz, 2H, CH), 7.12 (d, $J = 8.2$ Hz, 2H, CH), 7.03 (d, $J = 9.0$ Hz, 2H, CH), 4.03 (s, 3H, CH₃N), 3.85 (s, 3H, CH₃O), 2.31 (s, 3H, CH₃). – ¹³C NMR (63 MHz, CDCl₃): $\delta = 167.4$ (C=Se), 160.4, 151.6, 144.2, 135.2, 133.7, 129.7, 128.7, 128.2, 119.9, 114.6 (C_{aryl}, C_{imin}), 55.4 (CH₃O), 38.9 (CH₃N), 20.9 (CH₃). – ⁷⁷Se NMR (76 MHz, CDCl₃): $\delta = 92.3$ (s). – MS (DEI): $m/z = 402$ [M, ⁸⁰Se]⁺, 387, 360, 314, 296, 290, 268, 227, 213, 188, 161, 147, 133, 108, 91, 82, 77, 59, 44, 28. – C₁₈H₁₈N₄O₂Se (401.3): calcd. C 53.87, H 4.52, N 13.96; found C 53.85, H 4.42, N 13.92.

4-(4-Bromophenyl)-4,5-dihydro-1-methyl-5-selenoxo-N-p-tolyl-1H-1,2,4-triazole-3-carboxamide (15b)

This compound was obtained as colorless needles (77 mg, 17 % yield), m.p. 245.2–246.5 °C (dec.). – ¹H NMR (250 MHz, CDCl₃): $\delta = 8.46$ (s, 1H, NH), 7.68 (d, $J = 8.6$ Hz, 2H, CH), 7.41 (d, $J = 8.4$ Hz, 2H, CH), 7.24 (d, $J = 8.6$ Hz, 2H, CH), 7.14 (d, $J = 8.4$ Hz, 2H, CH), 4.03 (s, 3H, CH₃N), 2.32 (s, 3H, CH₃). – ¹³C NMR (63 MHz, CDCl₃): $\delta = 167.3$ (C=Se), 151.5, 143.7, 134.7, 133.5, 132.7, 129.7, 129.4, 124.4, 112.0 (C_{aryl}, C_{imin}), 38.9 (CH₃N), 20.9 (CH₃). – ⁷⁷Se NMR (76 MHz, CDCl₃): $\delta = 101.7$ (s). – MS (DEI): $m/z = 450$ [M, ⁸⁰Se⁷⁹Br]⁺, 371, 344, 316, 263, 236, 209, 196, 184, 157, 133, 106, 91, 82, 77, 44, 28. – C₁₇H₁₅BrN₄OSe (450.2): calcd. C 45.35, H 3.36, Br 17.75, N 12.45; found C 45.38, H 3.39, Br 17.90, N 12.41.

4-(4-tert-Butylphenyl)-4,5-dihydro-1-methyl-5-selenoxo-N-p-tolyl-1H-1,2,4-triazole-3-carboxamide (15c)

This compound was obtained as colorless needles (90 mg, 21 % yield), m.p. 225.0 °C (dec.). – ¹H NMR (250 MHz, CDCl₃): $\delta = 8.46$ (s, 1H, NH), 7.55 (d, $J = 8.4$ Hz, 2H, CH), 7.40 (d, $J = 8.4$ Hz, 2H, CH), 7.28 (d, $J = 8.4$ Hz, 2H, CH), 7.12 (d, $J = 8.4$ Hz, 2H, CH), 4.03 (s, 3H, CH₃N), 2.31 (s, 3H, CH₃), 1.37 (s, 9H, C(CH₃)₃). – ¹³C NMR (63 MHz, CDCl₃): $\delta = 167.1$ (C=Se), 152.9, 151.7, 144.2, 135.3, 133.7, 133.0, 129.7, 127.0, 126.3, 120.1 (C_{aryl}, C_{imin}), 38.9 (CH₃N), 34.9 (C(CH₃)₃), 31.3 (C(CH₃)₃), 20.9 (CH₃). – ⁷⁷Se NMR (76 MHz, CDCl₃): $\delta = 91.7$ (s). – MS (DEI): $m/z = 428$ [M, ⁸⁰Se]⁺, 413, 322, 306, 294, 278, 238, 214, 199, 187, 173,

159, 133, 106, 91, 82, 77, 65, 28. – C₂₁H₂₄N₄OSe (427.4): calcd. C 59.01, H 5.66, N 13.11; found C 58.99, H 5.75, N 12.99.

4,5-Dihydro-1-methyl-5-oxo-N-p-tolyl-1H-1,2,4-triazole-3-carbothioamide (16)

This compound was obtained as yellow prisms (109 mg, 44 % yield), m. p. 206–210 °C. – ¹H NMR (250 MHz, CDCl₃): δ = 10.27, 9.89 (2s, 2H, NH), 7.74 (d, *J* = 8.4 Hz, 2H, CH), 7.24 (d, *J* = 8.2 Hz, 2H, CH), 3.55 (s, 3H, CH₃N), 2.37 (s, 3H, CH₃). – ¹³C NMR (63 MHz, CDCl₃): δ =

175.9 (C=S), 154.3, 142.2, 137.3, 135.2, 129.8, 122.7 (C_{aryl}, C=O, C_{imin}), 32.8 (CH₃N), 21.30 (CH₃). – MS (DEI): *m/z* = 248 [M]⁺, 215, 175, 149, 124, 106, 91, 65. – C₁₁H₁₂N₄OS (248.3): calcd. C 53.21, H 4.87, N 22.56, S 12.91; found C 53.10, H 4.80, N 22.52, S 12.95.

Acknowledgements

We thank AlzChem Trostberg GmbH, Clariant GmbH and Syngenta Crop Protection AG for support by chemicals. Furthermore, this work was supported by the Ministry of Education of Czech Republic (MSM 0021620822).

- [1] D. Pufky, R. Beckert, M. Döring, O. Walter, *Heterocycles* **2002**, 57, 1257–1264.
- [2] a) E. C. Taylor, H. M. L. Davies, R. J. Clemens, H. Yanagisawa, N. F. Haley, *J. Am. Chem. Soc.* **1981**, 103, 7660–7661; b) E. C. Taylor, H. M. L. Davies, W. T. Lavell, N. D. Jones, *J. Org. Chem.* **1984**, 49, 2204–2208; c) E. C. Taylor, H. M. L. Davies, J. S. Hinkle, *J. Org. Chem.* **1986**, 51, 1530–1536; d) E. C. Taylor, D. M. Sobieray, *Tetrahedron* **1991**, 47, 9599–9620.
- [3] a) J. Fleischhauer, R. Beckert, W. Günther, H. Görls, *Synthesis* **2006**, 2885–2890; b) J. Fleischhauer, R. Beckert, J. Weston, M. Schmidt, H. Flammersheim, H. Görls, *Synthesis* **2006**, 514–518.
- [4] a) R. Beckert, J. Fleischhauer, A. Darsen, J. Weston, S. Schenk, A. Batista, E. Anders, H. Görls, M. Döring, D. Pufky, O. Walter, *Heterocycles* **2005**, 65, 1311–1320; b) J. Fleischhauer, R. Beckert, W. Günther, S. Kluge, S. Zahn, J. Weston, D. Berg, H. Görls, *Synthesis* **2007**, 2839–2848.
- [5] R. Beckert, R. Mayer, *J. Prakt. Chem.* **1982**, 324, 227–236.
- [6] a) R. Beckert, M. Gruner, I. Seidel, R. J. Kuban, *Monatsh. Chem.* **1989**, 120, 1125–37; b) R. Beckert, M. Gruner, *J. Prakt. Chem.* **1992**, 334, 611–18; c) C. Kaepplinger, R. Beckert, A. Darsen, W. Günther, *Sulfur Letters* **2001**, 24, 281–289.
- [7] a) G. I. Kornis in *Comprehensive Heterocyclic Chemistry*, II, Vol. 4 (Ed.: R. C. Storr), Pergamon Press Inc., New York **1996**, chapter 4.10, pp. 379–408; b) R. K. Smalley in *Comprehensive Heterocyclic Chemistry*, II, Vol. 6 (Ed.: A. J. Boulton), Pergamon Press Inc., New York **1996**, chapter 6.17, pp. 737–781.
- [8] a) H. Beyer, E. Bulka, F. W. Beckhaus, *Chem. Ber.* **1959**, 2593–2599; b) H. Beyer, *Z. Chem.* **1969**, 9, 361–369; c) W. D. Pfeiffer, J. Buhrow, E. Bulka, *Wissensch. Z. der Ernst-Moritz-Arndt-Universität Greifswald, Math.-Nat.wiss. Reihe* **1988**, 37, 38–41; d) R. E. Busby, T. W. Dominey, *J. Chem. Soc., Perkin Trans.* **1980**, 2, 890–899; e) T. Jira, W. D. Pfeiffer, K. Lachmann, U. Epperlein, *Pharmazie* **1994**, 49, 401–406.
- [9] a) T. Jira, A. Stelzer, W. D. Pfeiffer, C. Schopplich, S. Siegert, M. Kindermann, *Pharmazie* **1997**, 52, 831–835; b) W. Pfeiffer, E. Dilk, H. Rossberg, P. Langer, *Synlett* **2003**, 2392–2394.
- [10] a) M. Morvan, G. Nadler, R. G. Zimmermann, *J. Heterocycl. Chem.* **1991**, 28, 1365–1368; J. Schröder, A. Henke, H. Wenzel, H. Brandstetter, H. G. Stammeler, A. Stammeler, W. D. Pfeiffer, H. Tschesche, *J. Med. Chem.* **2001**, 44, 3231–3243; c) A. M. Mahran, N. A. Hassan, *Arch. Pharm. Res.* **2006**, 29, 46–49; d) J. Matysiak, *Eur. J. Med. Chem.* **2007**, 42, 940–947.
- [11] a) H. M. Hassaneen, A. Shetta, A. S. Shawali, *J. Heterocycl. Chem.* **1980**, 17, 1185–1187; b) A. O. Abdelhamid, S. M. Abdelgawad, S. F. El-Sharnoby, *Phosphorus, Sulfur Silicon Relat. Elem.* **2002**, 177, 2699–2709; c) A. T. S. Omer, N. M. Rateb, A. O. Abdelhamid, *Phosphorus, Sulfur Silicon Relat. Elem.* **2003**, 178, 2363–2371; d) S. M. Abdel-Gawad, M. S. Elgendy, A. O. Abdelhamid, *J. Sulfur Chem.* **2005**, 26, 21–31; e) N. Rateb, *Phosphorus, Sulfur Silicon Relat. Elem.* **2005**, 180, 2361–2372; f) O. V. Firsova, T. S. Dolgushina, V. A. Polukeev, E. M. Ioannisyanyan, V. E. Zavodnik, A. I. Stash, V. K. Bel'skii, V. A. Galishev, *Russ. J. Org. Chem.* **2005**, 41, 762–768.
- [12] U. Petersen, H. Heitzer, *Justus Liebig's Ann. Chem.* **1973**, 944–960.
- [13] a) M. Koketsu, Y. Yamamura, H. Ishihara, *Heterocycles* **2006**, 68, 1191–1200; b) G. L. Sommen, A. Linden, H. Heimgartner, *Helv. Chim. Acta* **2007**, 90, 641–651.
- [14] COLLECT, Nonius Kappa-CCD Software, Nonius, B. V., Delft, (The Netherlands) **1998**.
- [15] HKL DENZO, SCALEPACK: Z. Otwinowski, W. Minor, *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography*, Part A (Eds.: C. W. Carter Jr, R. M. Sweet), Academic Press, New York **1997**, pp. 307–326.
- [16] G. M. Sheldrick, *Acta Crystallogr.* **1990**, A46, 467.
- [17] G. M. Sheldrick, SHELXL-97, Program for the Refine-

- ment of Crystal Structures, University of Göttingen, Göttingen (Germany) **1997**.
- [18] XP (version 4.1). Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin (USA) **1990**.
- [19] a) O. J.-C. Nicaise, D. M. Mans, A. D. Morrow, E. V. Hefti, E. M. Palkovacs, R. K. Singh, M. A. Zukowska, M. D. Morin, *Tetrahedron* **2003**, 59, 6433–6443; b) ^1H NMR (250 MHz, $[\text{D}_6]\text{DMSO}$): δ = 10.90, 10.30 (2s, 2 H, NH), 7.86 (d, J = 8.8 Hz, 2 H, CH), 7.55 (d, J = 8.8 Hz, 2 H, CH), 6.91 (s, 2 H, CH), 2.23, 2.11 (2s, 9 H, CH_3); c) R. Bauer, *Ber. Dtsch. Chem. Ges.*, **1907**, 40, 2653; d) ^1H NMR (250 MHz, CDCl_3): δ = 7.60 (d, J = 8.8 Hz, 2 H, CH), 7.07 (d, J = 8.8 Hz, 2 H, CH), 6.94 (s, 2 H, CH), 2.33, 2.11 (2s, 9 H, CH_3).